Clinical Trial

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the use of ctDNA measurements to guide first-lien therapy choice for patients with advanced or metastatic melanoma. Primary endpoints include progression-free survival. Secondary study endpoints include objective response rate and incidence and severity of immune-related adverse events.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-22
Trial Details
NCT Number NCT07504796
Lead Sponsor NYU Langone Health
Conditions Metastatic Melanoma, Advanced Melanoma
Enrollment 90 participants
Start Date 2026-04-13
Primary Completion 2029-05 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-21